Literature DB >> 31091471

Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis.

Sara Touhami1, Isabelle Audo2, Céline Terrada3, Alain Gaudric4, Phuc LeHoang3, Valérie Touitou3, Bahram Bodaghi5.   

Abstract

Masquerade syndromes represent a large set of ophthalmological entities that mimic inflammatory conditions. Any delay in their diagnosis may be correlated with systemic dissemination or worsening of the causal disease and, therefore, with poor prognosis. One of the disadvantages of the new potent treatments of uveitis is the delay that they can induce in the diagnosis of neoplastic intraocular infiltrations. Thorough and careful clinical examination of all patients referred for uveitis, especially when they are Caucasian, over 50 years of age, and with posterior segment involvement, is of paramount importance in this context. Ancillary investigations and often-invasive histo-pathologic evaluation of tissue specimens or ocular fluids are regularly required in these situations. The most common masquerade syndrome is primary vitreoretinal lymphoma (PVRL). New molecular diagnostic tools may be helpful in challenging cases lacking cytological confirmation. Therapeutic strategies targeting tumoral cells in the eye and also in the central nervous system can improve the life expectancy of affected patients. In this review, we discuss diagnostic strategies and current therapies in PVRL and provide an overview of other conditions that can mimic primary ocular inflammation, especially in the field of oncology and its new therapeutic armamentarium.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyloidosis; Cancer associated retinopathy; Leukemia; Lymphoma; Masquerade syndromes; Melanoma associated retinopathy; Retinoblastoma

Mesh:

Year:  2019        PMID: 31091471     DOI: 10.1016/j.preteyeres.2019.05.002

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  5 in total

1.  Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.

Authors:  Juliette Varin; Margaret M Reynolds; Nassima Bouzidi; Sarah Tick; Juliette Wohlschlegel; Ondine Becquart; Christelle Michiels; Olivier Dereure; Robert M Duvoisin; Catherine W Morgans; José-Alain Sahel; Quentin Samaran; Bernard Guillot; José S Pulido; Isabelle Audo; Christina Zeitz
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

2.  Coats-like response in tubercular subretinal abscess masquerading as melanoma as the initial manifestation of miliary tuberculosis.

Authors:  Nivedita Nair; Sreelakshmi Kummamuri; S Sudharshan; Vikas Khetan
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

3.  Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma.

Authors:  Xin-Yu Zhao; Tian-Tian Cheng; Li-Hui Meng; Wen-Fei Zhang; You-Xin Chen
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

4.  The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper.

Authors:  Justine R Smith; Alexandra L Farrall; Janet L Davis; Joke H de Boer; Anthony J Hall; Manabu Mochizuki; H Nida Sen; Hiroshi Takase; Ninette H Ten Dam-van Loon; Valérie Touitou; Daniel V Vasconcelos-Santos; David J Wilson; Steven Yeh; Mark H B Radford
Journal:  BMJ Open       Date:  2022-07-28       Impact factor: 3.006

5.  Ocular Inflammation Induced by Immune Checkpoint Inhibitors.

Authors:  Florence Chaudot; Pascal Sève; Antoine Rousseau; Alexandre Thibault Jacques Maria; Pierre Fournie; Pierre Lozach; Jeremy Keraen; Marion Servant; Romain Muller; Baptiste Gramont; Sara Touhami; Habeeb Mahmoud; Pierre-Antoine Quintart; Stéphane Dalle; Olivier Lambotte; Laurent Kodjikian; Yvan Jamilloux
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.